Ketamine shows promise for treatment-resistant bipolar depression
Adjunctive IV ketamine was tied to significant antidepressant effects vs. midazolam among people with treatment-resistant bipolar depression, a new randomized controlled trial shows.
According to Diana K. Orsini, MSc, MPH, from the University of Toronto in Canada, and colleagues, prior trials on the safety and efficacy of ketamine for depression have produced “limited evidence in bipolar disorder.”
“Patient complexity and theoretical safety concerns (ie, risk of ketamine-emergent mania or psychosis) have contributed to the exclusion of bipolar disorder,” they wrote in